Physician profile
Brian S Parsley
NPI 1366522781
$530,566.31
in general payments reported to CMS, 2019-2025
15 companies · $74K in 2025
The $74K reported for 2025 was more than what 96% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127K · 2020: $101K · 2021: $65K · 2022: $89K · 2023: $36K · 2024: $39K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $73K · Royalty Or License: $71K · Food and Beverage: $1,764 · Travel and Lodging: $1,661 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $73,142.87 |
| Royalty Or License | $70,918.89 |
| Food and Beverage | $1,764.42 |
| Travel and Lodging | $1,661.34 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conformis, INC. | $405,520.18 | 2019-2023 | Itotal Identity Cruciate Retaining Knee Replacement System, Itotal Cruciate Retaining (Cr) Knee Replacement System, Actera Hip Stem |
| Restor3d, INC. | $109,593.17 | 2024-2025 | |
| Think Surgical, INC. | $9,734.49 | 2019 | |
| Zimmer Biomet Holdings, INC. | $2,914.24 | 2021-2025 | Persona, Oxford |
| Synthes Gmbh | $1,650.00 | 2023 | |
| Stryker Corporation | $486.84 | 2019-2024 | Mako |
| Becton, Dickinson and Company | $220.80 | 2024 | Channel Drain |
| Pacira Pharmaceuticals Incorporated | $192.82 | 2022-2023 | Exparel, Zilretta, Iovera |
| Depuy Synthes Sales INC. | $67.51 | 2020-2024 | Orthovisc, Monovisc |
| Pacira Therapeutics, INC. | $60.16 | 2020-2021 | |
| Heron Therapeutics, INC. | $52.74 | 2025 | Zynrelef |
| Lilly USA, LLC | $25.87 | 2024 | Zepbound, Jardiance |
| Ethicon US, LLC | $24.65 | 2024 | Stratafix, Vistaseal, Ethicon |
| Medical Device Business Services, INC. | $22.84 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$79,200.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Parsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.